Exelixis EXEL COMETRIQ — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's cometriq — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's COMETRIQ — total revenues?
- Exelixis (EXEL) reported COMETRIQ — total revenues of $2.2M in Q1 2026.
- How has Exelixis's COMETRIQ — total revenues changed year-over-year?
- Exelixis's COMETRIQ — total revenues decreased by 8.6% year-over-year, from $2.41M to $2.2M.
- What is the long-term trend for Exelixis's COMETRIQ — total revenues?
- Over 4 years (2021 to 2025), Exelixis's COMETRIQ — total revenues has grown at a -20.1% compound annual growth rate (CAGR), from $23.21M to $9.44M.
- What does COMETRIQ — total revenues mean?
- The total revenue earned from sales of the Cometriq oncology treatment.
- How do you interpret COMETRIQ — total revenues?
- An increase indicates strong market demand or successful penetration in the indicated cancer treatment segments, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment standards.
- How does COMETRIQ — total revenues compare across companies?
- Comparable to product-specific net sales figures reported by other biopharmaceutical companies for their primary oncology assets, often benchmarked against therapeutic area peers.